The Company is committed to leveraging its products and services to establish a potential new standard of care across multiple malignant tumor applications.
The Company is a healthcare solution provider dedicated to the development and commercialization of brachytherapy TPS specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors.
FTTPS is technologically advanced and has a wide range of clinical indications. FTTPS is widely used in diseases caused by many types of malignant tumors, including but not limited to prostate cancer, lung cancer, pancreatic cancer, liver cancer, esophageal cancer, and breast cancer.
The Company offers personalized and inclusive services that catered to the specific requirements of its clients.
公司致力于利用我们的产品和服务，在多种恶性肿瘤应用中建立潜在的新护理标准。
我们是一家医疗解决方案提供商，致力于开发和商业化专门用于放射性粒籽植入的近距离治疗计划软件，粒籽植入治疗是一种通过在患者体内放置放射源来杀死癌细胞和缩小肿瘤的治疗癌症患者的放射疗法。
FTTPS技术先进，具有广泛的临床适应症。FTTPS广泛应用于多种恶性肿瘤引起的疾病，包括但不限于前列腺癌、肺癌、胰腺癌、肝癌、食管癌、乳腺癌等。
公司提供根据客户的具体要求提供个性化和包容性的服务。
The Company focuses on key growth strategies to realize its mission:
· Enhance ability to attract, incentivize and maintain good relationships with talented professionals. The Company believes its success greatly depends on the ability to attract, incentivize and maintain long-term relationships with talented professionals. In addition, the Company aims to keep long-term relationships with third-party development teams or experts.
· Continue to invest in research and development. The Company attributes part of its success to our continued investment in and focus on R&D.
The Company emphasizes quality control in all aspects of its operations to ensure its products meet stringent internal standards, international and industry standards, as well as detailed requirements of various laws and regulations relating to medical devices, including but not limited to the registration and filings for medical devices, the production and operation license, the production and quality management.
The TPS market is characterized by rapid product development, technological advances, intense competition and a strong emphasis on proprietary products. Across all product lines and product tiers, The Company faces direct competition both domestically in China and internationally. Factors such as price, value, customer support, brand recognition, reputation, and product functionality, reliability, and compatibility are key considerations in the competition.
As of 2023, Beijing Feitian holds a market share of 61.2% in terms of the total number of installed brachytherapy TPS in the market.
The Company’s mission is to provide innovative healthcare solutions and world-class service to become a reliable partner with hospitals, physicians and patients.
公司专注于关键发展战略以实现其使命：
· 提高吸引、激励人才并与之保持良好关系的能力。公司相信其成功在很大程度上取决于吸引、激励和保持与有才能的专业人士的长期关系的能力。此外，公司旨在与第三方开发团队或专家保持长期合作关系。
· 持续投资研究开发。公司的成功部分归功于其对研发的持续投资和专注。
公司在经营的各个环节都注重质量控制，确保产品符合严格的内部标准、国际标准和行业标准，以及与医疗器械有关的各种法律法规的详细要求，包括但不限于医疗器械的注册和备案、生产经营许可证、生产和质量管理。
治疗计划软件市场的特点是产品开发迅速，技术进步，竞争激烈，并着重强调专有产品。在所有产品线和产品层次上，公司在中国国内和国际上都面临着直接竞争。价格、价值、客户支持、品牌识别、声誉、产品功能、可靠性和兼容性等因素是竞争中的关键考虑因素。
截至2023年，北京飞天在近距离治疗TPS的安装总量中占有61.2%的市场份额。
我们的使命是提供创新医疗解决方案和世界一流的服务，成为医院、医生和患者可靠的合作伙伴。
|
